Medicine and Dentistry
Gefitinib
100%
Surfactant Protein A
77%
Epidermal Growth Factor Receptor Kinase Inhibitor
44%
Pneumonia
33%
Interstitial Lung Disease
33%
Patient
33%
Lung Cancer
22%
Lipopolysaccharide
22%
Surfactant Protein
22%
Therapeutic Procedure
22%
Lung
22%
In Vitro
11%
Adverse Event
11%
Protein Expression
11%
Epidermal Growth Factor
11%
Bronchoalveolar Lavage Fluid
11%
Lung Adenocarcinoma
11%
Intranasal Drug Administration
11%
Lipopolysaccharide-Induced Lung Inflammation
11%
Cells
11%
Pathogen
11%
Pharmacology, Toxicology and Pharmaceutical Science
Gefitinib
100%
Surfactant Protein A
77%
Epidermal Growth Factor Receptor Kinase Inhibitor
44%
Pneumonia
33%
Interstitial Lung Disease
33%
Lung Cancer
22%
Lipopolysaccharide
22%
Mouse
22%
Adverse Event
11%
Epidermal Growth Factor
11%
Lung Adenocarcinoma
11%
Lipopolysaccharide-Induced Lung Inflammation
11%
Infectious Agent
11%
Biochemistry, Genetics and Molecular Biology
Gefitinib
100%
Surfactant Protein A
77%
Epidermal Growth Factor Receptor
44%
Receptor Tyrosine Kinase Inhibitors
44%
Lipopolysaccharide
33%
Mouse
22%
Protein Expression
11%
Epidermal Growth Factor
11%
Liquid
11%
Infectious Agent
11%